文献速递头颈部肿瘤放疗放疗物理与技术

头颈部碳离子放疗后鼻泪管阻塞的剂量学预测参数

Dosimetric parameters predictive of nasolacrimal duct obstruction after carbon-ion radiotherapy for head and neck carcinoma.
PubMed 文献 · Radiother Oncol · 2019-08-19

这项单中心前瞻性研究纳入28例头颈部非鳞状细胞癌患者,分析碳离子放疗后鼻泪管阻塞的发生率及预测剂量学参数。中位随访60.3个月,1级和2级鼻泪管阻塞发生率分别为46%和7%,无3级及以上毒性。V10至V60范围内受照鼻泪管体积在阻塞阳性患者中显著更高,ROC曲线确定的截断值在全剂量范围内分类准确率超过96%。

要点

  • 碳离子放疗后鼻泪管阻塞以1级为主,发生率为46%,2级为7%,无3级及以上毒性。
  • V10至V60各剂量水平下,阻塞阳性患者鼻泪管受照体积均显著高于阴性患者。
  • ROC曲线确定的V10-V60截断值对阻塞阳性分类准确率超过96%。

核心结论

  • 本研究展示了头颈部碳离子放疗后鼻泪管阻塞的发生率及预测剂量学参数,有助于优化碳离子放疗计划。

研究设计与样本

  • 单中心前瞻性研究,纳入28例头颈部非鳞状细胞癌患者,多数肿瘤位于鼻腔和上颌窦。
  • 碳离子放疗剂量为57.6或64.0 Gy(RBE),分16次给予。
  • 鼻泪管阻塞按CTCAE 4.0标准记录,截断值通过ROC曲线分析确定。

主要发现

  • 中位随访60.3个月,1级鼻泪管阻塞发生率为46%(13/28),2级为7%(2/28),无3级及以上毒性。
  • 在V10、V20、V30、V40、V50和V60各剂量水平,阻塞阳性患者的鼻泪管受照体积均显著高于阻塞阴性患者(p < 0.001)。
  • ROC曲线确定的截断值在全V10-V60范围内对阻塞阳性的分类准确率超过96%。

关键数值与推荐

  • 碳离子放疗剂量为57.6或64.0 Gy(RBE),分16次。
  • V10至V60的截断值由ROC曲线分析确定,分类准确率超过96%。

临床怎么用

  • 在头颈部碳离子放疗计划优化时,可参考V10-V60剂量学参数评估鼻泪管阻塞风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Little information is available on the risk factors for nasolacrimal duct obstruction after radiotherapy for head and neck tumors. We investigated the incidence and predictive dosimetric parameters for nasolacrimal duct obstruction following carbon-ion radiotherapy for head and neck tumors. MATERIALS AND METHODS: Twenty-eight patients with head and neck non-squamous cell carcinoma were analyzed in this single-institution prospective study. More than half of the tumors were located in the nasal cavity and maxillary sinus. Carbon-ion radiotherapy consisting of 57.6 or 64.0 Gy(relative biological effectiveness; RBE) in 16 fractions was administered. Nasolacrimal duct obstruction was recorded according to Common Terminology Criteria for Adverse Events version 4.0. Cutoff values were determined using receiver operating characteristic (ROC) curve analysis. VX indicates the volume irradiated with X Gy(RBE). RESULTS: The median follow-up period was 60.3 months. Incidences of Grade 1 and 2 nasolacrimal duct obstructions were 46% (13/28) and 7% (2/28), respectively; no Grade 3 or greater toxicities were recorded. Throughout the dose range, the volumes of the irradiated nasolacrimal ducts were significantly higher in the obstruction-positive patients than in the obstruction-negative patients (p < 0.001 for V10, V20, V30, V40, V50, and V60). Cutoff values determined by the ROC curve analysis classified the obstruction-positive patients with an accuracy of >96% over the entire range of V10-V60. CONCLUSION: The incidence and predictive dosimetric parameters for nasolacrimal duct obstruction after carbon-ion radiotherapy were demonstrated in a prospective cohort. These data should help optimize carbon-ion radiotherapy treatments for patients with head and neck tumors.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kubo N, Kubota Y, Kawamura H, et al. Dosimetric parameters predictive of nasolacrimal duct obstruction after carbon-ion radiotherapy for head and neck carcinoma. Radiother Oncol. 2019. PMID: 31439449. doi:10.1016/j.radonc.2019.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。